<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389909</url>
  </required_header>
  <id_info>
    <org_study_id>MRAP060309</org_study_id>
    <nct_id>NCT00389909</nct_id>
  </id_info>
  <brief_title>Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants</brief_title>
  <official_title>Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jean Michel Hascoet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maternite Regionale Universitaire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doxapram is used to stimulate respiration. For a given dose, the fluctuations in
      concentrations observed in infants' blood may be wide, leading to a risk of lack of efficacy
      or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of
      this study is to compare a dosage regimen based only on patient's weight, to another one
      using a dosing chart taking into account weight, age and gender.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doxapram is a drug used to stimulate respiration in neonates prematurely born and failing to
      breathe. For a given dose, the fluctuations in concentrations of drug observed in infants'
      blood might be wide, leading to a risk of lack of efficacy of the treatment or of toxic
      effects. Two factors are linked to these fluctuations: age and gender. The aim of our study
      is to compare a dosage regimen based only on patient's weight, and another one using a dosing
      chart taking into account not only weight but also age and gender to prescribe the initial
      dose of doxapram. The final goal of this trial is to improve efficacy and tolerance of
      doxapram by minimizing the fluctuations in blood drug levels in premature neonates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma level of Doxapram and its active metabolite (ketodoxapram) at 48 hours after the onset of treatment.</measure>
    <time_frame>48 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (rate of significant apnea)</measure>
    <time_frame>1 Week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Premature Infants</condition>
  <condition>Apnea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment based on patient weight;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment based on a chart taking into account weight, age and gender</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxapram</intervention_name>
    <description>Dosing comparison between fixed scheduled and sex related dosage.
Dosing related to weight only versus chart taking into account weight, age and gender.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Dopram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature infants (&lt;37 weeks gestation)

          -  More than 1 significant Apnea q 8h (&gt; 20 sec or &lt; 20 sec with bradycardia or
             desaturation)

          -  Already treated with caffeine

        Exclusion Criteria:

          -  Intubation

          -  congenital malformation

          -  symptomatic apnea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Jeanne BOUTROY, PhD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Michel HASCOET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of NANCY France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maternite Regionale Universitaire</name>
      <address>
        <city>Nancy</city>
        <zip>54042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.maternite.chu-nancy.fr</url>
    <description>(home page of the hospital)</description>
  </link>
  <reference>
    <citation>Barb√© F, Hansen C, Badonnel Y, Legagneur H, Vert P, Boutroy MJ. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. Ther Drug Monit. 1999 Oct;21(5):547-52.</citation>
    <PMID>10519454</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2006</study_first_submitted>
  <study_first_submitted_qc>October 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maternite Regionale Universitaire</investigator_affiliation>
    <investigator_full_name>Jean Michel Hascoet</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Premature infants</keyword>
  <keyword>Apnea</keyword>
  <keyword>Doxapram</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxapram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

